Download PDF
Phlebologie 2014; 43(02): 93-98
DOI: 10.12687/phleb2179-2-2014
Medical history
Schattauer GmbH

Curious stories surrounding the discovery and development of conventional antithrombotics

Article in several languages: English | deutsch
M. Haug
Further Information

Publication History

Received: 11 November 2013

Accepted: 09 January 2014

Publication Date:
04 January 2018 (online)

    Permissions and Reprints

Summary

In former times, the discovery of a therapeutic effect was usually a chance event. The route to clinical use was frequently long and arduous and often associated with curious stories, as is the case with the antithrombotic agents, heparin, aspirin and warfarin.

Heparin: Who deserves the credit for discovering the substance? The student, Jay McLean, who, in addition to finding the thromboplastic cephalin components he was searching for, also chanced upon an anticoagulant component? Or his supervisor, who later took up McLean’s “chance discovery” and also isolated anticoagulant components that were chemically distinct from McLean’s but became the precursor substance of today’s heparin?

Aspirin: Long known as an analgesic and antipyretic drug, it has enjoyed a second career in cardiovascular medicine. It was not until 1967 that aspirin’s antiplatelet activity was recognised. Its second career began with the marketing authorisation for transient ischaemic attack (TIA) and myocardial infarction at the beginning of 1980. Until that time, the story of Dr Craven had remained unknown. In 1950, he had published his observations in “obscure” journals, stating that none of his patients who were taking aspirin had suffered a myocardial infarction.

Warfarin: Around 1920, thousands of North American cattle were dying of internal haemorrhage. The deaths were found to be due to the ingestion of stored “sweet clover”. It took years to discover the explanation: transformation of the non-toxic coumarin in the hay to the anticoagulant dicoumarol through fungal infection. Synthesis soon followed, with clinical use as an antithrombotic drug, although the substance enjoyed much greater success as the rat poison warfarin. It was not used again in humans until a soldier survived his suicide attempt thanks to vitamin K administration.

Keywords

Anticoagulation - vascular surgery - drug therapy - history of discovery
 

  • References

  • 1 Wardrop D, Keeling D. The story of the discovery of heparin and warfarin. British Journal of Hematology 2008; 141: 757-763.
    CrossrefGoogle Scholar
  • 2 Lam CR. The Strange Story of Jay McLean, the Discoverer of Heparin. Henry Ford Hosp Med J 1985; 33 (01) 18-23.
    Google Scholar
  • 3 McLean J. The thromboplastic action of cephalin. Am J Physiol 1916; 41: 250-257.
    Google Scholar
  • 4 Howell WH, Holt E. Two new factors in blood coagulation – heparin and prothrombin. Am J Physiol 1918; 47: 328-341.
    CrossrefGoogle Scholar
  • 5 Howell WH. The purification of heparin and its presence in the blood. Am J Physiol 1925; 71: 553-562.
    Google Scholar
  • 6 Best CH. Preparation of Heparin and its Use in the First Clinical Cases. Circulation 1959; 19: 79-86.
    CrossrefGoogle Scholar
  • 7 Scott DA, Charles AF. Studies on Heparin III. The Purification of Heparin. J Biol Chem 1933; 102: 437-448.
    Google Scholar
  • 8 Murray GDW, Best CH. The Use of Heparin in Thrombosis. Ann Surg 1938; 108: 163-177.
    CrossrefGoogle Scholar
  • 9 Jorpes E. Heparin: A Mucopolysaccharide and an Active Antithrombotic Drug. Circulation 1959; 19: 87-91.
    CrossrefGoogle Scholar
  • 10 Marcum JA. William Henry Howell and Jay McLean: the experimental context for the discovery of heparin. Perspectives in Biology and Medicine 1990; 33: 214-230.
    CrossrefGoogle Scholar
  • 11 Marcum JA. The origin of the dispute over the discovery of heparin. Journal of the History of Medicine and Allied sciences 2000; 55: 37-66.
    CrossrefGoogle Scholar
  • 12 McLean J. The discovery of heparin. Circulation 1959; 19: 75-78.
    CrossrefGoogle Scholar
  • 13 Jorpes E. The Early History of Heparin. Annals of the New York Academy of Sciences 1964; 115: 392-398.
    CrossrefGoogle Scholar
  • 14 Schmidt-Mülheim A. Beiträge zur Kenntnis des Peptons und seiner physiologischen Bedeutung. Archiv für Anatomie und Physiologie / Physiologische Abteilung. Archiv für Physiologie. Berlin. Vereinigung wissenschaftlicher Verlage 1880; 4: 33-56.
    Google Scholar
  • 15 Doyon M. Rapports du foie avec la coagulation du sang. Journal de Physiologie 1912; 14: 229-224.
    Google Scholar
  • 16 Kohl F. Ein „Jahrhundertpharmakon wird Hundert. Schmerz 1999; 13 (05) 341-346.
    CrossrefGoogle Scholar
  • 17 Internetquelle: Bellis M. History of Aspirin. http://inventors.about.com/library/inventors/blaspirin.htm?p=1 (9.3.2013)
  • 18 Witthauer K. Aspirin, ein neues Salicylpräparat. Die Heilkunde 1899; 3: 396
    Google Scholar
  • 19 Sneader W. The discovery of aspirin: a reappraisal. BMJ 2000; 321: 1591-1594.
    CrossrefGoogle Scholar
  • 20 Sneader W. Drug Discovery: A History. New York:: John Wiley and Sons; 2005
    Google Scholar
  • 21 Eichengrün A. 50 Jahre Aspirin. Pharmazie 1949; 4: 582-584.
    Google Scholar
  • 22 Vaupel E. Arthur Eichengrün – Tribute to a forgotten chemist, entrepreneur and German jew. Angew Chem Int Ed 2005; 44: 3344-3355.
    CrossrefGoogle Scholar
  • 23 Internetquelle: Recent Rapid Responses 2001. Alsfasser H. Assumptions instead of Facts. 30 January 2001. Helmstaedter A. Is there a need for reappraisal? 9 March 2001. http://www. bmj.com/content/321/7276/1591?tab=responses
  • 24 Mueller RL, Scheidt S. History of Drugs for Thrombotic Disease – Discovery, Development and Directions for the Future. Circulation 1994; 89: 432-449.
    CrossrefGoogle Scholar
  • 25 Gibson PC. Aspirin in the treatment of vascular disease. Lancet 1949; 2: 1172-1174.
    Google Scholar
  • 26 Weiss HJ. The discovery of the antiplatelet effect of aspirin: a personal reminiscence. J Thromb Haemost 2003; 1: 1969-1875.
    Google Scholar
  • 27 Vane JR. Inhibition of Prostaglandin Synthesis as a Mechanism of Action for Aspirin-like Drugs. Nature 1971; 231: 232-235.
    Google Scholar
  • 28 Zylka-Menhorn V. 100 Jahre Acetylsalicylsäure – Arzneistoff mit (un-)endlichem Potential?. Deutsches Ärzteblatt 1997; 31 32: A-2054-A-2056.
    Google Scholar
  • 29 Miner J, Hoffhines A. The Discovery of Aspirin’s Antithrombotic Effects. Te Heart Inst J 2007; 34: 179-186.
    Google Scholar
  • 30 Craven LL. Acetylsalicylic acid: posssible preventive of coronary thrombosis. Ann West Med Surg 1950; 4: 95-99.
    Google Scholar
  • 31 Craven LL. Prevention of coronary and cerebral thrombosis. Miss Valley Med J 1953; 78: 213-215.
    Google Scholar
  • 32 Link KP. The discovery of dicumarol and its sequels. Circulation 1959; 19: 97-107.
    CrossrefGoogle Scholar
  • 33 Last JA. The missing link:the story of Karl P. Link. Toxicological Sciences 2002; 66: 4-6.
    CrossrefGoogle Scholar
  • 34 Link KP. The anticoagulant from spoiled sweet clover hay. Harvey Lectures 1943; 34: 162-207.
    Google Scholar
  • 35 Schofield FW. Hemorrhagic sweet clover disease in cattle. CanVet Rec 1922; 3: 74-75.
    Google Scholar
  • 36 Roderick LM. The pathology of sweet clover disease in cattle. J Am Vet Med Assoc 1929; 74: 314-325.
    Google Scholar
  • 37 Campbell HA, Link KP. Studies on the hemorrhagic sweet clover disease. IV. The isolation and crystallization of the hemorrhagic agent. Journal of Biological Chemistry 1941; 138: 21-33.
    Google Scholar
  • 38 Stahman MA, Huebner CF, Link KP. Studies on the hemorrhagic sweet clover disease: V. Identification and synthesis of the hemorrhagic agent. J Biol Chem 1941; 138: 513-527.
    Google Scholar
  • 39 Duxbury BM, Poller L. The oral anticoagulant saga: past, present, and future. Clin Appl Thromb Hemost 2001; 7 (04) 269-275.
    CrossrefGoogle Scholar
  • 40 Internetquelle: Wikipedia. Warfarin – Medical Use, Pesticide Use. http://en.wikipedia.org/w/index.php?title=Warfarin&oldid=80526729 (29.05.2013)